v3.25.1

Summary of significant transactions - Gilead Collaboration Agreement (Details) € in Millions, $ in Millions |  |  |  |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Jan. 08, 2025 item | Oct. 01, 2023 | Aug. 23, 2019 EUR (€) | Aug. 23, 2019 USD ($) | Jul. 14, 2019 | Dec. 31, 2023 | Dec. 31, 2024 item | Aug. 23, 2019 USD ($)
Spin-off |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Number Of Entities Following Spin Off | 2 |  |  |  |  |  |  |
Gilead collaboration agreement |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Global Research And Development Collaboration Term |  |  |  |  | 10 years |  |  |
Upfront Payment Received |  |  | € 3,569.8 | $ 3,950 |  |  |  |
Equity Investment from Gilead. |  |  | € 960.1 |  |  |  |  | $ 1,100
Number of Performance Obligations |  |  |  |  |  |  | 3 |
Gilead collaboration agreement | Filgotinib drug license | Gilead |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Future global development cost sharing ratio before predetermined level |  |  |  |  |  | 100.00% |  |
Gilead collaboration agreement | Filgotinib drug license | Original Agreement | Gilead |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Cost Share For Global Development Activities |  |  |  |  | 25.00% |  |  |
Future global development cost sharing ratio before predetermined level |  |  |  |  | 25.00% |  |  |
Gilead collaboration agreement | Filgotinib drug license | First Revised Agreement | Gilead |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Cost Share For Global Development Activities |  |  |  |  |  |  | 50.00% |
Future global development cost sharing ratio before predetermined level |  |  |  |  |  |  | 50.00% |
Gilead collaboration agreement | Filgotinib drug license | Second Revised Agreement | Gilead |  |  |  |  |  |  |  |
Summary Of Significant Transaction [line items] |  |  |  |  |  |  |  |
Future global development cost sharing ratio before predetermined level |  | 100.00% |  |  |  |  |  |

X
- Definition It represents the cost share mechanism for the future development activities, development and sales milestones and royalties. + References No definition available. + Details
Name: | glpg_CostShareForGlobalDevelopmentActivities
Namespace Prefix: | glpg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of ratio at which future development cost will be shared before predetermined level. + References No definition available. + Details
Name: | glpg_FutureGlobalDevelopmentCostsSharingRatioBeforePredeterminedLevel
Namespace Prefix: | glpg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of contract for global research and collaboration. + References No definition available. + Details
Name: | glpg_GlobalResearchAndDevelopmentCollaborationTerm
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entities following intended separation. + References No definition available. + Details
Name: | glpg_NumberOfEntitiesFollowingSpinOff
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of performance obligations. + References No definition available. + Details
Name: | glpg_NumberOfPerformanceObligations
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent summary of significant transaction. + References No definition available. + Details
Name: | glpg_SummaryOfSignificantTransactionLineItems
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash inflow received as upfront payment. + References No definition available. + Details
Name: | glpg_UpfrontPaymentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of instruments held by the entity that provide evidence of a residual interest in the assets of another entity after deducting all of its liabilities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_EquityInstrumentsHeld
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_AnnouncingOrCommencingImplementationOfMajorRestructuringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsScenarioAxis=glpg_OriginalAgreementScenarioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsScenarioAxis=glpg_FirstRevisedAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsScenarioAxis=glpg_SecondRevisedAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |